Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 5 of 5 results for tadalafil

  1. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

    NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology

    Technology appraisal guidance
    Published
    23 January 2013

    Sections for TA273

  2. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 December 2014

  3. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    12 August 2014

  4. Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Evidence summary
    Published
    23 May 2013